Andrew Saykin's, PsyD research program focuses on precision medicine for the early detection of Alzheimer’s disease and related dementias. His laboratory utilizes the integration of advanced multimodal high throughput neuroimaging, cognitive neuroscience, and multiple “omics” data, such as gene and protein/metabolite networks, to identify novel biomarkers of disease mechanisms and potential therapeutic targets of disease. Saykin’s research also encompasses the study of cognitive/memory deficits as they relate to cancer, traumatic brain injury, temporal lobe epilepsy, schizophrenia and other brain diseases.
Get involved
Curious to learn more about Saykin's work and ongoing research efforts in neuroimaging and Alzheimer's disease?
Saykin discusses path toward precision medicine
Multimodal Advanced Neuroimaging/Network
analysis and Systems Biology
In Alzheimer’s disease, neuropathology may be present 15-20 years 
prior to symptom onset, necessitating the need for early detection and intervention. Therefore, multimodal high throughput neuroimaging provides an in vivo evolving readout of neuropathology of brain disease, allowing for the investigation of clinical problems and the analysis of brain structure, function, activity and connectivity.
This information is integrated with advanced analytics that utilize multi-omics datasets, such as transcriptomics, metabolomics, proteomics, and genomics, in a systems biology approach that simulates complex biological systems and interactions. In unison, these complex tools aid in the identification of biomarkers for early risk, which are important for characterizing pathophysiology, identifying novel targets for therapeutic development and assessing the response to treatment.
prior to symptom onset, necessitating the need for early detection and intervention. Therefore, multimodal high throughput neuroimaging provides an in vivo evolving readout of neuropathology of brain disease, allowing for the investigation of clinical problems and the analysis of brain structure, function, activity and connectivity. This information is integrated with advanced analytics that utilize multi-omics datasets, such as transcriptomics, metabolomics, proteomics, and genomics, in a systems biology approach that simulates complex biological systems and interactions. In unison, these complex tools aid in the identification of biomarkers for early risk, which are important for characterizing pathophysiology, identifying novel targets for therapeutic development and assessing the response to treatment.
leading research
25
active grants and subcontracts
$19 million
in annual grant funding
more than 60
collaborating faculty
current research funding
Indiana Alzheimer’s Disease Research Center (IADRC)
Memory Circuitry in MCI and Early Alzheimer’s Disease Prodrome: Molecular Drivers
Cognitive Aging, Alzheimer’s disease, and Cancer-related Cognitive Decline
Ultrascale Machine Learning to Empower Discovery in Alzheimer’s Disease Biobanks
Korean Brain Aging Study, Longitudinal Endophenotypes and Systems Biology
Genetics Core
Northern California Institute/Res/Edu
Training Grant on Alzheimer's Disease and ADRD at Indiana University
Informatics Algorithms for Genomic Analysis of Brain Imaging Data
Duke University (Prime: NIH)
Gut Liver Brain Biochemical Axis in Alzheimer’s Disease
Leveraging Neuroimaging Biomarkers to Understand the Role of Social Networks in Alzheimer's Disease
Investigators
Andrew J. Saykin, PsyD
Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center
Postdoctoral trainees
Evgeny Jenya Chumin, PhD
Medical Neuroscience
Cecily Swinford, PhD
Medical Neuroscience
Thea Rosewood, PhD
Medical and Molecular Genetics
graduate students
Soumilee Chaudhuri
Kaitlyn Dybing
Desarae Dempsey
Lauren Hirschfeld